BLRD Research Career Scientist Award Application

BLRD 研究职业科学家奖申请

• 批准号: 10471518
• 负责人: Michal A Olszewski
• 金额: --
• 依托单位: VETERANS HEALTH ADMINISTRATION
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-04-01 至 2027-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10471518
• 关键词: Acquired Immunodeficiency Syndrome; Acute Respiratory Distress Syndrome; Animal Model; Antibiotic Therapy; Antibody Therapy; Antifungal Agents; Area; Autoimmune Diseases; Award; Bioinformatics; Brain; COVID-19 pandemic; COVID-19 patient; COVID-19/ARDS; CXCR3 gene; Caliber; Cause of Death; Cerebrum; Chronic lung disease; Clinical Data; Clinical Research; Code; Collaborations; Communicable Diseases; Communities; Complement; Cryptococcosis; Cryptococcus; Cryptococcus neoformans; Death Domain; Dendritic Cells; Dendritic cell activation; Development; Disease; Drug resistance; Drug toxicity; Effectiveness; Epigenetic Process; Exhibits; Exposure to; Foundations; Funding; Future; Genes; Genetic Transcription; Goals; Grant; HIV; Healthcare; Host Defense; Host Defense Mechanism; Human; Hypersensitivity; Immune; Immune Evasion; Immune response; Immune system; Immunity; Immunocompetent; Immunocompromised Host; Immunologics; Immunologist; Immunology; Immunotherapeutic agent; Immunotherapy; Individual; Infection; Inflammation; Inflammatory; Integration Host Factors; Interleukin-10; Intervention; Knowledge; Location; Lung; Lung infections; Malignant Neoplasms; Mentors; Microbe; Modification; Molecular; Morbidity - disease rate; Mycoses; National Institute of Allergy and Infectious Disease; Organ Transplantation; Organism; Outcome; Pathogenesis; Pathologic; Pathology; Pathway interactions; Patients; Phenotype; Process; Publications; Published Comment; Publishing; RIPK3 gene; Receptor Signaling; Regimen; Research; Resistance development; Risk; Risk Factors; Role; SARS-CoV-2 infection; Science; Scientist; Services; Signal Pathway; Signal Transduction; Site; Source; Substance abuse problem; T cell response; T-Lymphocyte; TNF gene; Testing; Therapeutic; Toxic effect; Transplant Recipients; United States National Institutes of Health; Validation; Veterans; Virulence Factors; Work; antimicrobial; career; chronic infection; cytokine; design; editorial; experience; fungus; global health; high risk; human data; immunomodulatory therapies; immunopathology; immunoregulation; interest; microbial; microorganism interaction; military service; monocyte; mortality; mouse model; mutant; neglect; neutrophil; novel therapeutics; novel vaccines; pathogen; patient population; pre-clinical; prevent; programs; response; risk stratification; scavenger receptor; stem; therapeutic target; translational study; tumor; vaccine strategy

Dr. Olszewski is an immunologist with over 25 years of experience in studies of inflammatory/infectious diseases in the lungs, CNS and at the systemic level with over 20 years of research at the Ann Arbor VAHS. Overall career goal is to expand the understanding of host pathogen interactions, specifically the effect of microbe- and host-derived signals on the fate of the immune response. Understanding of these interactions will create a foundation for the development of safe and effective immunomodulatory therapies that will greatly enhance the effectiveness of antimicrobial therapeutics in persistent infections. Nominee’s lab has specialized in animal modeling and translational studies, applying these principles to a broader range of diseases as shown by more recent clinical data. His studies have mostly focused on host pathogen interactions between invasive fungus C. neoformans and the mammalian immune system. The studies of invasive fungal infections are of specific interest to the VA, because of the higher than average rate of immunocompromised patients among veterans and increased risk of exposure to various endemic and environmental fungi due to locations and conditions of military service that favor fungal exposures. Unfortunately, the invasive fungal infections have unacceptably high mortality rates, due to limited effectiveness of antifungal drugs, toxicity, and the high potential of fungal organisms to develop resistance to these drugs. Thus, it is crucial to understand the effects of immunomodulation on fungal disease from the perspective of the natural mechanisms of host defenses, mechanisms of immune evasion exhibited by fungi, and to explore pre-clinical approaches of immunomodulatory therapies. The long-standing support of VA BLR&D was one of the crucial factors that allowed our group to establish itself among leaders in cryptococcal and fungal immunology. Additional areas of work involve clinical studies looking into pathogenesis od ARDS in COVID19 patients and infections of GI track. The VA RCS Award will allow the nominee to continue his productive research career, successful mentoring of new scientists and to provide service to the research community at the VA and beyond.

Olszewski博士是一位免疫学家，有超过25年的研究经验 肺部、中枢神经系统和全身的炎性/感染性疾病超过20年 在安娜堡VAHS的研究。职业生涯的总体目标是扩大对主持人的理解 病原体的相互作用，特别是微生物和宿主衍生的信号对病原体命运的影响 免疫反应。对这些相互作用的理解将为 开发安全有效的免疫调节疗法，将极大地提高 抗菌药物治疗持续性感染的有效性。被提名者的实验室 专门从事动物建模和翻译研究，将这些原则应用于更广泛的 最近的临床数据显示了疾病的范围。 他的研究主要集中在入侵真菌C. 新生杆菌和哺乳动物的免疫系统。侵袭性真菌感染的研究包括 对退伍军人特别感兴趣，因为免疫受损的比率高于平均水平 退伍军人中的患者和暴露于各种地方病和环境的风险增加 由于服兵役的地点和条件有利于真菌的暴露。 不幸的是，侵袭性真菌感染的死亡率高得令人无法接受，原因是 抗真菌药物的效果有限、毒性和真菌生物的高潜力 对这些药物产生抗药性。因此，重要的是要了解 从寄主自然机制看真菌病的免疫调节 真菌表现出的防御、免疫逃避机制以及临床前探索 免疫调节治疗的方法。VA BLR&D的长期支持是其中之一 是哪些关键因素使我们的集团在隐球菌和 真菌免疫学。其他工作领域包括研究发病机制的临床研究。 COVID19例急性呼吸窘迫综合征与胃肠道感染退伍军人事务部RCS奖将允许 被提名人继续他富有成效的研究生涯，成功地指导新科学家和 为退伍军人事务部及以后的研究团体提供服务。